Consideration of Investments to Enhance Enterprise Value, Including M&A
First written in FY2018. 4 of 9 entries say "Advanced", first in 2026-06-04. Latest entry: 2026-10-02.
60 other companies' latest entry also says "Advanced".
- 2026-09-29AdvancedM&A and Subsidiary Changes
「当社は、長期的な成長戦略として自社製品のグローバル展開を加速させ、世界最大の市場である米国において事業基盤を早期に確立するため、米国 Cross Vascular 社を買収することを決定しました。」
M&Aを含む企業価値向上投資について、検討方針や投資枠の提示から、米国医療機器企業の全株式取得および増資の決議という実行段階へ進んだ。 - FY2026RaisedAnnual report
「The Company plans to accelerate growth investments going forward, including by establishing an M&A investment budget of ¥5 billion to ¥10 billion, continuing to invest in overseas startups to acquire future product pipelines, and investing to expand global manufacturing capacity.」
Regarding investments to enhance corporate value, including M&A, the Company has moved from its previous policy of considering such investments to a more specific policy of accelerating execution by establishing an investment budget of ¥5 billion to ¥10 billion. - 2026-06-04AdvancedGeneral Meetings of Shareholders
「We plan to accelerate growth investment going forward. In addition to establishing an M&A investment framework of ¥5.0 billion to ¥10.0 billion, we will continue to invest in overseas startups to acquire future product pipelines and in expanding global manufacturing capacity.」
The scale of the investment framework and the objectives of investment in overseas startups and manufacturing capacity became more concrete as part of investments to enhance enterprise value, including M&A. - FY2023RestatedAnnual report
「Going forward, if an investment is expected to contribute to enhancing the corporate value of the Group, we will consider investments including M&A and other transactions.」
The Company has reiterated its policy of considering investments including M&A, conditional on their contribution to enhancing corporate value. - FY2020RaisedAnnual report
「We intend to invest retained earnings in the development and production of proprietary products that leverage our strengths, the development of treatment areas outside the cardiovascular field, M&A aimed at overseas expansion, and the acquisition of marketing rights to secure a product pipeline, which are among our medium-term challenges, thereby achieving sustained growth in corporate value.」
The investment policy including M&A has been given more specific objectives: developing business areas outside cardiovascular care, expanding overseas, and acquiring distribution rights. - FY2019RestatedAnnual report
「Going forward, if an investment is expected to contribute to enhancing the corporate value of the Group, we will consider investments including M&A and other transactions.」
The Company has reiterated its policy of considering investments including M&A, conditional on their contribution to enhancing corporate value. - FY2018First statedAnnual report
「Going forward, if an investment is expected to contribute to enhancing the corporate value of the Group, we will consider investments including M&A and other transactions.」
The Company has explicitly stated for the first time, in its explanation of sources of capital, its policy of considering investments including M&A, conditional on their expected contribution to enhancing corporate value.